OMX Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Glyphic Biotechnologiesglyphic.bioin𝕏Feb 2024
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Joshua Yang(Founder & CEO)Daniel Estandian(Founder)Ed Boyden(Founder)Jimmy Yun(Director)
BoardCraig Asher(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.